These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37182603)

  • 1. Impactful improvements to Medicare Part D immunosuppressive drug coverage.
    Potter L; Crowther B; McDermott JK
    Am J Transplant; 2023 Sep; 23(9):1468-1470. PubMed ID: 37182603
    [No Abstract]   [Full Text] [Related]  

  • 2. A multicenter case series documenting Medicare Part D plan denials of immunosuppressant drug coverage for organ transplant recipients.
    Lushin EN; McDermott JK; Truax C; Lourenco LM; Mariski M; Melaragno JI; Potter LM
    Am J Transplant; 2021 Feb; 21(2):889-896. PubMed ID: 32976706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplant recipients are vulnerable to coverage denial under Medicare Part D.
    Potter LM; Maldonado AQ; Lentine KL; Schnitzler MA; Zhang Z; Hess GP; Garrity E; Kasiske BL; Axelrod DA
    Am J Transplant; 2018 Jun; 18(6):1502-1509. PubMed ID: 29446874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare program: Medicare Advantage and prescription drug programs MIPPA drug formulary & protected classes policies. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2009 Jan; 74(11):2881-8. PubMed ID: 19385109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression.
    Donohue JM; Zhang Y; Aiju M; Perera S; Lave JR; Hanlon JT; Reynolds CF
    Am J Geriatr Psychiatry; 2011 Dec; 19(12):989-97. PubMed ID: 22123272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Medicare Part D prescription claims for biologic and nonbiologic immunosuppressive medications by dermatologists.
    Gronbeck C; Feng PW; Feng H
    J Am Acad Dermatol; 2021 Mar; 84(3):848-851. PubMed ID: 33068642
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicare part D research and policy highlights, 2012: impact and insights.
    Lau DT; Stubbings J
    Clin Ther; 2012 Apr; 34(4):904-14. PubMed ID: 22417714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare Part D research highlights and policy updates, 2013: impact and insights.
    Stubbings J; Lau DT
    Clin Ther; 2013 Apr; 35(4):402-12. PubMed ID: 23541710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
    Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the US Medicare Part D coverage gaps on medication use among patients with depression and heart failure.
    Baik SH; Rollman BL; Reynolds CF; Lave JR; Smith KJ; Zhang Y
    J Ment Health Policy Econ; 2012 Sep; 15(3):105-18. PubMed ID: 23001279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare part D's exclusion of benzodiazepines and fracture risk in nursing homes.
    Briesacher BA; Soumerai SB; Field TS; Fouayzi H; Gurwitz JH
    Arch Intern Med; 2010 Apr; 170(8):693-8. PubMed ID: 20421554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.
    Kadatz M; Gill JS; Gill J; Formica RN; Klarenbach S
    J Am Soc Nephrol; 2020 Jan; 31(1):218-228. PubMed ID: 31704739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
    Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
    J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare Part D: selected issues for plan sponsors, pharmacists, and beneficiaries in 2009.
    Stubbings J; DePue RJ
    Am J Manag Care; 2009 Sep; 15(9):645-9. PubMed ID: 19747029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of Medicare prescription drug coverage on the use of antidementia drugs.
    Fowler NR; Chen YF; Thurton CA; Men A; Rodriguez EG; Donohue JM
    BMC Geriatr; 2013 Apr; 13():37. PubMed ID: 23621892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D.
    Madden JM; Adams AS; LeCates RF; Ross-Degnan D; Zhang F; Huskamp HA; Gilden DM; Soumerai SB
    JAMA Psychiatry; 2015 Feb; 72(2):179-88. PubMed ID: 25588123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-base: limitations on Medicare Part D coverage of off-label prescriptions.
    Medicare Rights Center
    Care Manag J; 2008; 9(3):142-8. PubMed ID: 18847098
    [No Abstract]   [Full Text] [Related]  

  • 18. Centers for Medicare and Medicaid Services Support for Medication Therapy Management (Enhanced Medication Therapy Management): Testing Strategies for Improving Medication Use Among Beneficiaries Enrolled in Medicare Part D.
    Brandt NJ; Cooke CE
    Clin Geriatr Med; 2017 May; 33(2):153-164. PubMed ID: 28364988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare Part D and potentially inappropriate medication use in the elderly.
    Donohue JM; Marcum ZA; Gellad WF; Lave JR; Men A; Hanlon JT
    Am J Manag Care; 2012 Sep; 18(9):e315-22. PubMed ID: 23009330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the impact of coverage gaps in the Medicare Part D drug benefit.
    Hudson N
    Find Brief; 2008 Apr; 11(3):1-3. PubMed ID: 18441611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.